About this item:

27 Views | 5 Downloads

Author Notes:

John Anderson, john.anderson1@hcahealthcare.com

J.A. organized and structured the data. J.R.G. and D.F.K. researched the data. E.M. researched the data and provided case study details and ambulatory glucose profile reports. J.A. is the guarantor of this work, and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

The production of this video series and associated materials was funded by an educational grant from Novo Nordisk, Inc. Writing and editorial support in the preparation of this digital publication and executive summary was provided by Gregory Scott, PharmD, RPh, on behalf of the Illinois Academy of Family Physicians, Primary Care Metabolic Group, and Primary Care Education Consortium. The content for this article and the associated video series was produced according to the policies of the Accreditation Council for Continuing Medical Education. Novo Nordisk had no input into the topic, forum discussion, or any content for this article or its accompanying videos.

J.A. serves as an advisor, consultant, and/or speaker for Alfa Sigma, AstraZeneca, Abbott Diabetes Care, Bayer, Eli Lilly, Gelesis, Novo Nordisk, and Sanofi. J.R.G. serves on speaker’s bureaus and/or as a consultant to Abbott Diabetes Care, Boehringer Ingelheim, Eli Lilly, Intuity Technology, Novo Nordisk, and Xeris. D.F.K. serves on advisory boards and/or speaker’s bureaus for Abbott Diabetes Care, Cequr, Dexcom, Eli Lilly, Novo Nordisk, Sanofi, and Xeris and has stock options in Pendulum. E.M. serves on advisory boards and/or speaker’s bureaus or is a consultant to Abbott Diabetes Care, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck, and Novo Nordisk and has received research support from Abbott Diabetes Care and Pendulum. No other potential conflicts of interest relevant to this article were reported.

Subject:

Keywords:

  • diabetes

Optimizing the Use of Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes: Executive Summary

Tools:

Journal Title:

Clinical Diabetes

Volume:

Volume 40, Number 3

Publisher:

, Pages 265-269

Type of Work:

Article | Final Publisher PDF

Abstract:

The type 2 diabetes treatment algorithm recommended by the American Diabetes Association (ADA) has undergone major changes in the past 5 years based on a greater understanding of the pathophysiology of diabetes and extensive investigation of the clinical profiles of glucose-lowering medications (1,2). As a consequence, the glucagon-like peptide 1 (GLP-1) receptor agonists are now recommended in several clinical situations for people with type 2 diabetes (2).

Copyright information:

© 2022 by the American Diabetes Association

This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Export to EndNote